PubRank

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Clinical Trial ID NCT01176461

PubWeight™ 38.88‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01176461

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
2 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
3 Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013 2.70
4 Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013 2.07
5 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
6 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
7 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
8 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
9 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
10 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
11 Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 2015 1.14
12 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
13 Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013 0.96
14 Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013 0.94
15 Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014 0.89
16 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
17 Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 2016 0.86
18 Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. Front Oncol 2014 0.85
19 Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014 0.84
20 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
21 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
22 Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother 2011 0.80
23 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
24 Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2011 0.79
25 Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol 2014 0.78
26 The role of checkpoints in the treatment of GBM. J Neurooncol 2015 0.75
27 Revisiting of cancer vaccine?-Specific immunotherapy comes to field with the biomarker. Ann Transl Med 2016 0.75
Next 100